Laumas Sandeep, CFO and CBO of Instil Bio ($TIL), sold shares on the open market twice in the last year for a total of about $702,000. The most recent sale occurred on September 10, 2025. These transactions rank 5,734th among 11,678 insiders, well below the average sale amount of $8.6 million across 6.4 transactions. No open market purchases were recorded.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan. 9, 2026 | BioXcel Therapeutics, Inc. | $BTAI | Laumas Sandeep | Director | A | Stock Option (Right to Buy) | 17000 | $0.00 | 17,000.0000 | 14,196,000 | 9999.99% | 0.12% |
| Sept. 10, 2025 | Instil Bio, Inc. | $TIL | Laumas Sandeep | CFO and CBO | M | Employee Stock Option (right to buy) | 17000 | $0.00 | 17,000.0000 | 6,750,716 | 50.00% | 0.25% |
| Sept. 10, 2025 | Instil Bio, Inc. | $TIL | Laumas Sandeep | CFO and CBO | S | Common Stock | 17539 | $23.04 | 12,461.0000 | 6,750,716 | 58.46% | 0.26% |
| Sept. 10, 2025 | Instil Bio, Inc. | $TIL | Laumas Sandeep | CFO and CBO | S | Common Stock | 12461 | $23.88 | 0.0000 | 6,750,716 | 100.00% | 0.18% |
| Sept. 10, 2025 | Instil Bio, Inc. | $TIL | Laumas Sandeep | CFO and CBO | M | Employee Stock Option (right to buy) | 13000 | $0.00 | 30,000.0000 | 6,750,716 | 30.23% | 0.19% |
| Sept. 10, 2025 | Instil Bio, Inc. | $TIL | Laumas Sandeep | CFO and CBO | M | Common Stock | 17000 | $11.60 | 17,000.0000 | 6,750,716 | 9999.99% | 0.25% |
| Sept. 10, 2025 | Instil Bio, Inc. | $TIL | Laumas Sandeep | CFO and CBO | M | Common Stock | 13000 | $12.68 | 30,000.0000 | 6,750,716 | 76.47% | 0.19% |
| July 28, 2025 | Unicycive Therapeutics, Inc. | $UNCY | Laumas Sandeep | Director | A | Stock Options | 21200 | $0.00 | 41,286.0000 | 12,302,059 | 105.55% | 0.17% |
| April 25, 2025 | Instil Bio, Inc. | $TIL | Laumas Sandeep | CFO and CBO | A | Employee Stock Option (right to buy) | 44851 | $0.00 | 44,851.0000 | 6,558,927 | 9999.99% | 0.68% |
| Sept. 18, 2024 | Instil Bio, Inc. | $TIL | Laumas Sandeep | CFO and CBO | A | Employee Stock Option (right to buy) | 45000 | $0.00 | 45,000.0000 | 6,503,913 | 9999.99% | 0.69% |
| June 10, 2024 | BioXcel Therapeutics, Inc. | $BTAI | Laumas Sandeep | Director | A | Stock Option (Right to Buy) | 17000 | $0.00 | 17,000.0000 | 1,929,000 | 9999.99% | 0.88% |
| Feb. 10, 2024 | Instil Bio, Inc. | $TIL | Laumas Sandeep | CFO and CBO | A | Employee Stock Option (right to buy) | 80000 | $0.00 | 80,000.0000 | 6,503,913 | 9999.99% | 1.23% |
| Sept. 5, 2023 | Unicycive Therapeutics, Inc. | $UNCY | Laumas Sandeep | Director | A | Stock Options | 189236 | $0.00 | 200,864.0000 | 15,234,570 | 1627.42% | 1.24% |
| June 26, 2023 | BioXcel Therapeutics, Inc. | $BTAI | Laumas Sandeep | Director | A | Stock Option (Right to Buy) | 17000 | $0.00 | 17,000.0000 | 28,616,000 | 9999.99% | 0.06% |
| Jan. 8, 2023 | Instil Bio, Inc. | $TIL | Laumas Sandeep | CFO and CBO | A | Employee Stock Option (right to buy) | 415000 | $0.00 | 415,000.0000 | 6,503,913 | 9999.99% | 6.38% |
| March 4, 2022 | Instil Bio, Inc. | $TIL | Laumas Sandeep | CFO and CBO | A | Employee Stock Option (right to buy) | 234000 | $0.00 | 234,000.0000 | 0 | 9999.99% | 0.00% |